{"id":"W4286296265","doi":"10.1200/jco.2022.40.16_suppl.5000","title":"TheraP: <sup>177</sup>Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—Overall survival after median follow-up of 3 years (ANZUP 1603).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Cabazitaxel; Medicine; Docetaxel; Prostate cancer; Internal medicine; Oncology; Clinical endpoint; Hazard ratio; Progression-free survival; Cancer; Overall survival; Urology; Nuclear medicine; Clinical trial; Confidence interval; Androgen deprivation therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009168346,0.0008292375,0.001413291,0.0005124527,0.0002411647,0.0005745887,0.0006277936,0.001038928,0.006827543],"category_scores_gemma":[0.0009568753,0.0003786195,0.0009591308,0.0003358396,0.000602815,0.0006239782,0.0003012306,0.00160648,0.0008971231],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006224494,"about_ca_system_score_gemma":0.0008308934,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009036516,"about_ca_topic_score_gemma":0.003006543,"domain_scores_codex":[0.9996824,0.000183415,0.00002131969,0.00003565826,0.00002300956,0.00005414277],"domain_scores_gemma":[0.9996674,0.00009515422,0.00007429648,0.000016437,0.00001753854,0.0001293064],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9415204,0.008542749,0.0006913067,0.0006642106,0.0005246089,0.00004944921,0.0000690952,0.0006564091,0.006182787,0.0002114906,0.001380098,0.03950744],"study_design_scores_gemma":[0.6174557,0.3700269,0.00568448,0.00009551991,0.0008653698,0.0001008041,0.00006939248,0.001293043,0.00181487,0.0003769028,0.002190013,0.00002695067],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9910182,0.002801548,0.0002076824,0.0004355159,0.0003210482,0.001670293,0.000490834,0.00009607612,0.00295879],"genre_scores_gemma":[0.9905799,0.00152862,0.0007744715,0.000588554,0.0002302567,0.001929502,0.0005346098,0.00001682697,0.003817208],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006827543,"threshold_uncertainty_score":0.02284038,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.13108514094083,"score_gpt":0.4633682341905971,"score_spread":0.3322830932497671,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}